Lantern Pharma Reports the First Patient Dosing of LP-184 in the P-I Study for Advanced Solid Tumors Shots: The first patient has been dosed in the P-I trial evaluating the safety & tolerab
Shots:
- The first patient has been dosed in the P-I trial evaluating the safety & tolerability of escalating doses of LP-184 in 35 patients with advanced solid tumors
- The study focuses on determining the MTD & RP2D in patients with advanced solid tumors & recurrent high-grade gliomas, incl. GBM. Patients will be monitored for safety, PK, and clinical activity while dose escalation is planned with a minimum of 3 patient cohorts
- The P-IA portion of the trial is expected to be completed in H1’24. The company seeks to advance LP-184 into additional clinical trials for multiple solid tumor indications while Lantern’s subsidiary Starlight Therapeutics will advance the clinical development of LP-184 for all brain & CNS indications under the name STAR-001
Ref: Businesswire | Image: Lantern Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
